Answers are grounded in this paper and cite their sources.
Prospective cohort study finds sarcopenia independently elevates intradialytic hypotension risk in hemodialysis patients, highlighting the clinical value of assessing muscle mass and strength.
We aimed to determine how common sarcopenia is in the hemodialysis (HD) population and to investigate its independent link to intradialytic hypotension (IDH). Additionally, the study analyzed the predictive value of specific sarcopenia components for IDH. This prospective cohort study enrolled 236 hemodialysis (HD) patients across two centers of Lu’an Hospital, affiliated with Anhui Medical University. Participants were classified as having sarcopenia or not according to the 2019 AWGS guidelines. We assessed skeletal muscle index (SMI) through bioimpedance analysis, handgrip strength using a dynamometer, and gait speed via a 6-m walk. Over a two-year follow-up, patients were tracked for IDH events and clinical endpoints. A multivariate negative binomial regression model was applied to evaluate whether sarcopenia is independently associated with IDH risk and to examine the predictive value of its three constituent elements (SMI, grip strength, and gait speed). The study included a total of 236 patients, with a sarcopenia prevalence of 34.8% (82 cases). During the 2-year follow-up, 57,784 dialysis sessions were monitored, and 9001 (15.6%) IDH events occurred. Multivariate negative binomial regression analysis showed that sarcopenia was independently associated with a higher incidence of IDH (IRR = 1.69, 95% CI 1.21–2.36, P = 0.002). Component analysis identified that higher grip strength (IRR = 0.98, 95% CI 0.97–1.00, P = 0.034) and SMI (IRR = 0.86, 95% CI 0.74–0.99, P = 0.037) were significantly associated with reduced IDH risk, whereas gait speed showed no significant association ( P = 0.447). Sarcopenia is independently associated with higher IDH risk among HD patients. Therefore, screening for skeletal muscle mass and grip strength is recommended for early risk identification. Whether targeted interventions for sarcopenia can reduce IDH episodes and improve clinical outcomes requires further interventional studies to verify.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: